Trial Profile

An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 10 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Feb 2020 Results published in the Clinical Cancer Research
05 Jun 2018 Interim results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
19 Apr 2018 According to an Argos Therapeutics media release, based on the recently submitted protocol amendment focused on four co-primary endpoints of survival and review of the interim data the Company does not believe that it would achieve these endpoints if the trial were to be continued. After consulting with the principal investigators, the company has decided to discontinue the trial and has informed the FDA of its decision.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com